Hemolytic uremic syndrome (HUS) is a disease of nonimmune (Coombs negative) hemolytic
anemia, low platelet count, and renal impairment (1). Anemia is severe and …

Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor that inhibits cell cycle
progression and has proven to be a potent immunosuppressive agent for use in solid organ …

Thrombotic microangiopathy (TMA) is a serious complication of transplantation that
adversely affects kidney transplant recipient and allograft survival. Post-transplant TMA is …

Thrombotic microangiopathy (TMA) is one of the most devastating sequalae of kidney
transplantation. A number of published articles have covered either de novo or recurrent …

Sirolimus (rapamycin) is a macrocyclic lactone isolated from a strain of Streptomyces
hygroscopicus that inhibits the mammalian target of rapamycin (mTOR)-mediated signal …

Anemia is a highly prevalent disorder in recipients of renal allografts. Despite its frequent
occurrence, there is still uncertainty with regard to treatment targets and treatment options …

Renal function deteriorates in about half of patients undergoing other transplants. We report
the results of 105 renal biopsies from 101 nonrenal transplant recipients (bone marrow 14 …

Hemolytic uremic syndrome (HUS) is a systemic disease characterized by damage to
endothelial cells, erythrocytes and kidney glomeruli. A “typical” form of HUS follows …

Background Transplant‐associated thrombotic microangiopathy (TMA) syndromes are
reported to occur with increased frequency in transplant patients treated with siroliumus …

Background. Conversion from cyclosporine (CsA) to sirolimus (SRL) has mainly been done
in clinical conditions warranting calcineurin inhibitor discontinuation. Little is known about …